S. Loganathan

发表

Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer

M. Socinski, I. Bondarenko, C. Waller, 2021, Therapeutic advances in medical oncology.

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

H. Rugo, A. Manikhas, I. Bondarenko, 2021, Breast Cancer Research and Treatment.

Efficacy and Safety of Tregopil, a Novel, Ultra-Rapid Acting Oral Prandial Insulin Analog, as Part of a Basal-Bolus Regimen in Type 2 Diabetes: A Randomized, Active Controlled Phase 3 Study

H. Lebovitz, A. Cherrington, J. Panda, 2022, medRxiv.

Efficacy and safety of Tregopil, a novel, ultra-rapid acting oral prandial insulin analog, as part of a basal-bolus regimen in type 2 diabetes: a randomized, active-controlled phase 2/3 study

H. Lebovitz, A. Cherrington, A. Fleming, 2022, Expert opinion on pharmacotherapy.

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

H. Rugo, A. Manikhas, I. Bondarenko, 2021, Breast.

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial

H. Rugo, A. Manikhas, I. Bondarenko, 2017, JAMA.

Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications

S. Joshi, S. Athalye, S. Loganathan, 2020, Expert opinion on biological therapy.

REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicentre, single-arm, Phase IV Itolizumab Trial: RESURRECT

S. Athalye, B. Thakur, Chirag C Rathod, 2021, medRxiv.

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19

R. Guleria, S. Joshi, A. Trikha, 2020, medRxiv.

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study

S. Athalye, S. Loganathan, A. Marwah, 2021, Diabetes, obesity & metabolism.

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE‐2 (Recombinant Human INsulin Equivalence‐2) study

G. Andersen, S. Athalye, S. Loganathan, 2023, Diabetes, obesity & metabolism.

Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin 70/30 with US‐licensed HUMULIN® 70/30 formulation in healthy subjects: Results from the RHINE‐3 (Recombinant Human INsulin Equivalence‐3) study

O. Klein, S. Athalye, S. Loganathan, 2022, Diabetes, obesity & metabolism.

Insulin Tregopil: An Ultra-Fast Oral Recombinant Human Insulin Analog: Preclinical and Clinical Development in Diabetes Mellitus

S. Joshi, V. Sambandamurthy, S. Athalye, 2023, Drugs.

REcovery and SURvival of patients with moderate to severe acute REspiratory distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT

S. Athalye, Chirag C Rathod, S. Loganathan, 2023, Expert Opinion on Biological Therapy.